“The market value of the company has fallen through the floor. We’ve taken all the action we can to reduce costs, including laying off one-third of the workforce. We’re a small company, so that’s just six people.”

— Brent Norton, president/CEO of PreMD discussing why his company is requesting a second level review with the FDA for its 510(k) submission for expanded claims for its Prevu skin cholesterol test, “PreMD in ‘tough spot’ after FDA ruling on skin cholesterol test,” pp. 1, 6.